Abstract

Provided is a method for modulating RNA splicing by inducing a base mutation at a splice site or a base substitution in a polypyrimidine region. The method comprises expressing a targeting cytosine deaminase in a cell, to induce AG at a 3′ splice site of an intron of interest in a gene of interest to mutate into AA, or to induce GT at a 5′ splice site of the intron of interest in a gene of interest to mutate to AT, or to induce a plurality of Cs in a polypyrimidine region of the intron of interest in a gene of interest to respectively mutate into Ts. The method specifically blocks an exon recognition process, modulates a selective splicing process of endogenous mRNA, induces exon skipping, activates an alternative splice site, induces mutually exclusive exon conversion, induces intron retention, and enhances an exon.

IPC Classes  ?

• C12N 15/90 - Stable introduction of foreign DNA into chromosome
• C12N 15/52 - Genes encoding for enzymes or proenzymes
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 9/22 - Ribonucleases
• C12N 9/78 - Hydrolases (3.) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
• A61K 38/46 - Hydrolases (3)
• A61K 38/50 - Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy

Abstract

Disclosed are a full human broad-spectrum neutralizing antibody against respiratory syncytial virus and use thereof. Specifically, disclosed in the present invention are a full human monoclonal antibody 4F1 against a respiratory syncytial virus fusion protein (F protein) and pre-fusion F protein (preF protein), a nucleic acid sequence encoding said antibody and an antibody fragment, and a preparation method therefor. In vivo and in vitro experiments confirm that said 4F1 antibody can effectively prevent and control RSV infection, has low immunogenicity in the human body, can avoid immune rejection reactions mediated by heterogenetic antibodies such as human anti-mouse, and can be used clinically for preventing and treating respiratory syncytial virus infection.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• C07K 19/00 - Hybrid peptides
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 31/14 - Antivirals for RNA viruses

Abstract

Provided is the use of an ECM1 gene-knockout mouse in the screening of an anti-hepatic fibrosis drug. Specifically, provided is a method for preparing an animal model of hepatic fibrosis or related diseases thereof in non-human mammals, which method comprises the following steps: (a) providing a non-human mammalian cell and inactivating an ECM1 gene in the cell, thereby obtaining a non-human mammalian cell in which the ECM1 gene is inactivated; and (b) using the cell in which the ECM1 gene is inactivated obtained in step (a) to prepare an animal model of hepatic fibrosis or related diseases thereof in which the ECM1 gene is inactivated. The animal model is an effective animal model of hepatic fibrosis or related diseases thereof, may be used for studying hepatic fibrosis or related diseases thereof, and may be used in the screening and testing of a particular drug.

IPC Classes  ?

• C12N 15/09 - Recombinant DNA-technology
• A01K 67/027 - New or modified breeds of vertebrates
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 49/00 - Preparations for testing in vivo
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

Provided is application of ECM1 in the prevention and/or treatment of liver fibrosis-related diseases, specifically provided is the use of ECM1 gene, or protein or a promoter thereof for preparing a composition or a formulation, the composition or formulation being used for (a) preventing and/or treating of liver fibrosis-related diseases; and/or for (b) maintaining liver homeostasis. The ECM1 gene, or the protein or promoter thereof can significantly (i) prevent and/or treat cirrhosis-related diseases; and/or (ii) maintain the liver homeostasis. In addition, the ECM1 gene, or the protein or promoter thereof can also significantly (i) inhibit the occurrence of liver fibrosis-related diseases; and/or (ii) inhibit the activation of hepatic stellate cells (HSCs).

IPC Classes  ?

• C07K 19/00 - Hybrid peptides
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans

Abstract

Disclosed is a use of serine protease inhibitor Kazal type 1 (SPINK1) in the preparation of an agent for diagnosing or regulating cell senescence and tumors. SPINK1 plays an important biological role in SASP phenotype and a tumor microenvironment, and is closely correlated with prognosis after chemotherapy. Thus, SPINK1 can serve as a target for research on SASP phenotype regulation as well as anti-tumor research on the basis of tumor microenvironment, as a marker for prognostic assessment and pathological grading of tumor after chemotherapy, and as a target for developing a tumor-inhibiting drug.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to application of amphiregulin (AREG) in production of a cell senescence and tumor diagnosis or regulation preparation. The present invention first discloses that AREG exerts an important biological effect in a SASP and a tumor microenvironment, and is closely associated with prognosis after chemotherapy. Therefore, AREG can be taken as a target of SASP regulation research and tumor microenvironment-based anti-tumor research, a marker of prognosis evaluation and pathological classification after tumor chemotherapy, and a target for developing a tumor inhibition drug.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans

Abstract

Provided are a method for expanding a hepatocyte in vitro and an application. A culture system of a reprogrammed human hepatocyte is provided to serve as a proliferable intermediate cell between a mature hepatocyte and a hepatic progenitor cell. The liver repopulation ability of the hepatocyte was verified in animals. The method does not require the introduction of an exogenous gene into a hepatocyte, and the expansion of the hepatocyte can be realized by means of a conventional culture. The obtained hepatocyte is passable; and can be cultured to maturation to obtain a functional mature human hepatocyte.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 5/074 - Adult stem cells
• A61K 35/407 - LiverHepatocytes
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

A lacUV5 promoter variant of SEQ ID NO: 1, capable of promoting expression of T7 RNA polymerase to increase an expression level of an exogenous recombinant protein in Escherichia coli and extend expression time, thereby increasing production of the recombinant protein.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/68 - Stabilisation of the vector
• C12N 15/70 - Vectors or expression systems specially adapted for E. coli
• C12N 15/72 - Expression systems using regulatory sequences derived from the lac-operon
• C12P 21/00 - Preparation of peptides or proteins

Abstract

Provided are a baicalein- and wild baicalein-synthesizing microorganism, a preparation method for same, and applications thereof. By modifying a heterologous metabolic pathway of a host cell per a genetic engineering method, acquired is an engineered strain providing a high yield of baicalein and wild baicalein. Also provided is a process for utilizing the engineered strain to produce baicalein and wild baicalein.

IPC Classes  ?

• C12N 15/70 - Vectors or expression systems specially adapted for E. coli
• C12N 15/75 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
• C12N 15/81 - Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
• C12P 17/06 - Oxygen as only ring hetero atoms containing a six-membered hetero ring, e.g. fluorescein
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
• C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
• C07K 19/00 - Hybrid peptides
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 15/53 - Oxidoreductases (1)

Abstract

Disclosed are applications of flavonoid C-glycoside monomer compounds, vitexin, isovitexin, orientin, and isoorientin, in preparing an analgesic or a drug for promoting wound healing. The analgesic activity of isoorientin is significantly stronger than aspirin and rotundine. Vitexin and orientin have stronger effect of promoting wound healing.

IPC Classes  ?

• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The present invention provides a novel Bcl10 polymerization inhibitor and an application thereof. The Bcl10 polymerization inhibitor is polypeptide, and has (i) a function of inhibiting Bcl10 polymerization; (ii) the activity of inhibiting a CBM complex; (iii) the activity of selectively inhibiting the growth of a B cell lymphoma (such as ABC-DLBCL); and/or (iv) the activity of preventing and/or treating CBM complex-mediated diseases associated with NF-kB activation. The present invention further provides a preparation method for the polypeptide and an application thereof, and a pharmaceutical composition comprising the polypeptide.

IPC Classes  ?

• C07K 19/00 - Hybrid peptides
• C12N 15/62 - DNA sequences coding for fusion proteins
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61P 35/02 - Antineoplastic agents specific for leukemia
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

Provided are an HARP1 polypeptide-mediated intracellular transport and an application thereof in regulating a biological defense mechanism. The HARP1 and an HARP1-like (HL) polypeptide have characteristics of entering cells or tissues by means of a complex structure such as a cell wall and a cell membrane, and can be applied to establish an efficient transportation system, and helps exogenous active molecules enter cells. The HARP1 and the HL polypeptide further have effector activity, and can reduce plant defense response.

IPC Classes  ?

• C12N 15/11 - DNA or RNA fragmentsModified forms thereof

Abstract

A method and system for screening brain function-related behavioral paradigm indicators, and an application of the method, the indicators and the system in auxiliary diagnosis of brain dysfunctions, such as behavioral disorders, emotional disorders and neurodegenerative diseases. On the basis of the confirmatory combination of multiple statistical methods and big data of cases, a method and system for screening behavioral paradigm indicators is provided, and the method and system facilitates the simplification and selection of behavioral paradigm indicators so as to obtain behavioral paradigm indicators most relevant to various diseases. By means of big data analysis and the self-learning ability of the system, such as the self-learning ability of artificial intelligence, correspondence between updated and improved behavioral paradigm indicators and brain dysfunctions is used to provide a more objective diagnostic standard for brain disease diagnosis which are usually only determined by experience of clinicians.

IPC Classes  ?

• G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients

Abstract

low low low) of crops.

IPC Classes  ?

• C12N 15/54 - Transferases (2)
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• A01H 5/00 - Angiosperms, i.e. flowering plants, characterised by their plant partsAngiosperms characterised otherwise than by their botanic taxonomy
• C12N 9/10 - Transferases (2.)

Abstract

Provided are a RNAi target gene that is lethal to aphids and the use thereof. Specifically, provided are six gene fragments resulting in the death of aphid nymphs and/or death thereof in the adult stage based on RNA interference technology. The death of the aphids can be caused by spraying a dsRNA-containing composition onto plants to feed aphids or directly spraying same onto the skin of the aphids.

IPC Classes  ?

• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression

Abstract

Provided are a rice mutant miR393am having brown planthopper resistance and salt tolerance, a miR393a inhibitor, and an application thereof. The miR393a inhibitor and a preparation or composition prepared therefrom can be used for (i) resisting to brown planthoppers, and/or (ii) enhancing plant stress resistance. Reducing the expression or activity of miR393a or miR393a active fragments in a plant can (i) resist to brown planthoppers (for example, reducing the honeydew amount and/or growth speed), and/or (ii) enhance plant stress resistance (such as salt tolerance).

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells

Abstract

Provided is a donor DNA having a specific repeated sequence, and a reagent kit for gene editing. Also provided is a repeat-mediated plant site-specific recombination method, comprising using the donor DNA having the specific repeated sequence, cleaving a specific site of a target gene using a site-specific cleaving nuclease, and integrating the donor DNA fragment into a cleavage site by using a homologous arm of the donor DNA.

IPC Classes  ?

• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

Provided is a reaction system for implementing gene targeted integration at a target site of a genome. The reaction system comprises: a donor DNA, which is double-stranded; a Cas9 protein, or an encoding nucleic acid thereof, or a first expression vector for expressing the Cas9 protein; and a sgRNA, or a second expression vector for expressing the sgRNA. The gene editing efficiency of a targeted integration policy is better than that of other existing gene editing technology, and there is no limit to the length of an inserted fragment.

IPC Classes  ?

• C12N 15/90 - Stable introduction of foreign DNA into chromosome
• C12N 15/89 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection

Abstract

AtALMT1, AtMATE, ALS3AtALMT1AtALMT1AtALMT1 may reduce the secretion of the organic acid (such as the malic acid) and enhance the sensitivity of the plants to aluminum toxicity.

IPC Classes  ?

• C07K 14/415 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from plants
• C12N 15/29 - Genes encoding plant proteins, e.g. thaumatin
• C12Q 1/6895 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae

Abstract

The present invention provides a proliferation culture medium and a differentiation culture medium for hepatocyte culture and preparation of liver organs. The proliferation culture medium and the differentiation culture medium are based on a culture medium for growth of mammalian cells, added with a supplemental L-Glutamine reagent, a pH regulator that maintains the pH stability of the culture medium, a primary cell culture antibiotic, a serum replacement, N-acetylcysteine, and an optional nicotinamide, plus one or more of a BMP inhibitor, a Wnt agonist, a growth factor, a ROCK signaling pathway inhibitor, a P38 signaling pathway inhibitor, a Notch signaling pathway inhibitor, dexamethasone, a BMP7 activator, and a cAMP activator. A functional liver organ can be obtained by culturing liver cells using the culture medium of the present invention.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

The present invention provides a plant genome site-directed substitution method. Specifically, the present invention relates to a nucleic acid construct. The present invention relates to using the nucleic acid construct of a specific structure, and successfully achieves sgRNA-directed base site-directed mutagenesis (such as a mutation from T to C or from A to G) in a plant for the first time.

IPC Classes  ?

• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• A01H 5/00 - Angiosperms, i.e. flowering plants, characterised by their plant partsAngiosperms characterised otherwise than by their botanic taxonomy

Abstract

A no-label reagent combination for gene editing, comprising: (i) a first nucleic acid construct, or a first vector containing the first nucleic acid construct; and (ii) a second nucleic acid construct, or a second vector containing the second nucleic acid construct. By using a nucleic acid construct of a specific structure, the site-directed knock-in and/or replacement of an RNA-guided base is successfully implemented in a plant.

IPC Classes  ?

• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• A01H 5/00 - Angiosperms, i.e. flowering plants, characterised by their plant partsAngiosperms characterised otherwise than by their botanic taxonomy

Abstract

Disclosed are a method for high-throughput analyzing proteins and an applicable library thereof. The method for analyzing throughput proteins comprises using a tagged semi-cloned mouse library and conducting a parallel indication analysis for multiple different target proteins of interest with one or more tag protein antibodies. In the tagged semi-cloned mouse library, each semi-cloned mouse is a semi-cloned mouse or a sexually propagated progeny thereof obtained by injecting an ovum into a single male haploid embryonic stem cell and then cultivating, the single male haploid embryonic stem cell comprises the gene expressing the fusion protein of the target protein of interest and the tag protein, and the semi-cloned mice can express the fusion protein of the target protein of interest and the tag protein. The method provides a system suitable for high-throughput in vivo, real-time and dynamic research for the study of biomacromolecules.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• C12N 5/0735 - Embryonic stem cellsEmbryonic germ cells
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

Provided is an application of an ICAM-1 marker and a regulating agent thereof in promoting or inhibiting differentiation of adipose-derived stem cells into adipose cells, and an application of ICAM-1 or detection reagent thereof in (a) detecting adipose-derived stem cells, and/or (b) determining the risk of a subject suffering from obesity and a corresponding diagnostic kit and method. Further provided is an in vitro non-therapeutic preparation method for fat cells.

IPC Classes  ?

• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

Provided for the first time in the present invention is a method for preparing a non-human primate somatic cell cloned animal, which method specifically comprises the steps of: (i) providing a reconstructed egg, wherein the egg comes from the non-human primate; (ii) activating the reconstructed egg to form an activated reconstructed egg or activated reconstructed embryo formed by the reconstructed egg; (iii) reprogramming (a) the activated reconstructed egg or (b) embryonic cells of the activated reconstructed embryo to obtain a reprogrammed reconstructed egg or reprogrammed reconstructed embryo; and (iv) regenerating the reprogrammed reconstructed egg or reprogrammed reconstructed embryo to obtain the non-human primate somatic cell cloned animal. The method of the present invention can significantly improve the developmental capacity of nucleus-transplanted embryos in non-human primates (such as monkeys).

IPC Classes  ?

• C12N 15/89 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• A01K 67/027 - New or modified breeds of vertebrates

Abstract

Provided is a method for preparing a non-human primate somatic cell cloned animal, wherein specifically, the method comprises the steps of: (i) providing a reconstructed egg from the non-human primate; (ii) activating the reconstructed egg to form an activated reconstructed egg or activated reconstructed embryo formed by the reconstructed egg; (iii) reprogramming (a) the activated reconstructed egg or (b) embryonic cells of the activated reconstructed embryo to obtain a reprogrammed reconstructed egg or reprogrammed reconstructed embryo; and (iv) regenerating the reprogrammed reconstructed egg or reprogrammed reconstructed embryo to obtain the non-human primate somatic cell cloned animal. The method can significantly improve the developmental capacity of nucleus-transplanted embryos in non-human primates (such as monkeys).

IPC Classes  ?

• C12N 5/16 - Animal cells
• C12N 15/09 - Recombinant DNA-technology

Abstract

Provided herein are methods for diagnosing and/or treating a new subtype of triple negative breast cancers (TNBC), as well as compositions and kits that can be used in such methods.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• A61P 35/00 - Antineoplastic agents

Abstract

Provided are a mutant HPPD polypeptide having high resistance to a herbicide and an encoding gene thereof, and an application thereof in an improved plant. The amino acid at position 282 of the mutant HPPD polypeptide is mutated from arginine to serine at a wild-type HPPD polypeptide. In addition, the mutant HPPD polypeptide further comprises an amino acid at position 349 that is mutated from glutamic acid to lysine, and/or an amino acid at position 156 that is mutated from alanine to valine. The mutated HPPD polypeptide can be used for cultivating plants having resistance to a herbicide having HPPD inhibition.

IPC Classes  ?

• C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• A01H 5/00 - Angiosperms, i.e. flowering plants, characterised by their plant partsAngiosperms characterised otherwise than by their botanic taxonomy

Abstract

Provided are a method for improving rice yield by jointly knocking out ABA receptor PYL family genes and a use thereof.

IPC Classes  ?

• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• C12N 15/29 - Genes encoding plant proteins, e.g. thaumatin
• C07K 14/415 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from plants
• A01H 1/00 - Processes for modifying genotypes

Abstract

A compound for treatment or prevention of obesity or diseases related to obesity, and an application thereof. Specifically, provided are a compound as represented by formula I, or a pharmaceutically-acceptable salt thereof, and a pharmaceutical composition containing the compound. The compound has multiple functions and can be used for treatment or prevention of obesity or diseases related to obesity.

IPC Classes  ?

• A61K 31/4355 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
• A61P 3/04 - AnorexiantsAntiobesity agents
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals

Abstract

Disclosed are a novel tumor microenvironment-related target TAK1 and an application thereof in inhibition of a tumor. TAK1, as a research target for SASP regulation, can be used as a marker in tumor diagnosis and prognosis, and can also be used as a tumor microenvironment specific target to develop tumor inhibitory drugs.

IPC Classes  ?

• A61K 31/335 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• A61K 38/43 - EnzymesProenzymesDerivatives thereof

Abstract

Provided is a method for modulating RNA splicing by inducing a base mutation at a splice site or a base substitution in a polypyrimidine region. The method comprising: expressing a targeted cytosine deaminase in a cell, to induce AG at a 3' splice site of an intron of interest in a gene of interest to mutate into AA, or to induce GT at a 5' splice site of the intron of interest in the gene of interest to mutate to AT, or to induce a plurality of Cs in a polypyrimidine region of the intron of interest in the gene of interest to respectively mutate into Ts. The method specifically blocks an exon recognition process, modulates a selective splicing process of endogenous mRNA, induces exon skipping, activates an alternative splice site, induces mutually exclusive exon conversion, induces intron retention, and enhances an exon.

IPC Classes  ?

• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

Provided is a method for modulating RNA splicing by inducing a base mutation at a splice site or a base substitution in a polypyrimidine region. The method comprising: expressing a targeted cytosine deaminase in a cell, to induce AG at a 3' splice site of an intron of interest in a gene of interest to mutate into AA, or to induce GT at a 5' splice site of the intron of interest in the gene of interest to mutate to AT, or to induce a plurality of Cs in a polypyrimidine region of the intron of interest in the gene of interest to respectively mutate into Ts. The method specifically blocks an exon recognition process, modulates a selective splicing process of endogenous mRNA, induces exon skipping, activates an alternative splice site, induces mutually exclusive exon conversion, induces intron retention, and enhances an exon.

IPC Classes  ?

• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

Provided in the present invention are an application of a Cas protein, a method for detecting a target nucleic acid molecule and a kit, the method for detecting a target nucleic acid molecule comprising: adding a guide RNA, Cas12a and a nucleic acid probe to a reaction system comprising a target nucleic acid molecule to be detected, and carrying out detection after reaction is complete.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

A method for preparing immunodeficient rats and an application thereof. Novel immunodeficient rats are obtained by a new method. By applying the immunodeficient rats, a model for cell transplantation such as hepatic cells and tumor cells is further established. The immunodeficient rats have a good application prospect.

IPC Classes  ?

• C12N 15/90 - Stable introduction of foreign DNA into chromosome
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A01K 67/02 - Breeding vertebrates

Abstract

The present invention provides a use of an agent for reducing CREBZF protein expression in a subject and/or an agent for reducing activity of CREBZF protein expressed in a subject in preparing a drug for ameliorating weight gain in the subject, reducing blood sugar and blood lipids in the subject, improving fat deposition in the liver of the subject, increasing glucose tolerance of the subject, and/or ameliorating lipid accumulation in hepatocytes of the subject. The present invention also provides a method for creating a CREBZF-knockout transgenic mouse.

IPC Classes  ?

• A61P 3/00 - Drugs for disorders of the metabolism
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor

Abstract

Provided are a glycosyltransferase, a mutant, and an in vitro glycosylation method. The method comprises the steps of: transferring a glycosyl group of a glycosyl donor to a hydroxyl group at the C-3 position of a tetracyclic triterpenoid compound in the presence of a glycosyltransferase to form a glycosylated tetracyclic triterpenoid compound, wherein the glycosyltransferase is a glycosyltransferase as shown in SEQ ID NO.:4 or a polypeptide derived therefrom, or a glycosyltransferase as shown in SEQ ID NO.:21 or a polypeptide derived therefrom.

IPC Classes  ?

• C12N 9/10 - Transferases (2.)
• C12P 33/00 - Preparation of steroids
• A01H 5/00 - Angiosperms, i.e. flowering plants, characterised by their plant partsAngiosperms characterised otherwise than by their botanic taxonomy
• C12N 15/54 - Transferases (2)

Abstract

The present invention relates to a group of glycosyltransferase, and an application thereof. Specifically, provided is using glycosyltransferase GT29-32, GT29-33, GT29-34, GT29-4, GT29-5, GT29-7, GT29-9, GT29-11, GT29-13, GT29-17, GT29-18, GT29-19, GT29-20, GT29-21, GT29-22, GT29-23, GT29-24, GT29-25, GT29-36, GT29-37, GT29-42, GT29-43, GT29-45, GT29-46, PNUGT29-1, PNUGT29-2, PNUGT29-3, PNUGT29-4, PNUGT29-5, PNUGT29-6, PNUGT29-7, PNUGT29-8, PNUGT29-9, PNUGT29-14, and PNUGT29-15, as well as derived polypeptides thereof to catalyze the first glycosyl at position C-20, the first glycosyl at position C-6, and the first glycosyl at position C-3 of a tetracyclic triterpene compound substrate to elongate a carbohydrate chain, thereby obtaining a catalytic reaction of ginsenoside products such as ginsenoside Rg3, ginsenoside Rd, ginsenoside Rb1, ginsenoside Rb3, saponin DMGG, saponin DMGX, gypenoside LXXV, gypenoside XVII, gypenoside XIII, gypenoside IX, notoginsenoside U, and notoginsenoside R1, notoginsenoside R2, notoginsenoside R3, 3-O-β-(D-xylopyranosyl)-β-(D-glucopyranosyl)-PPD, 3-O-β-(D-xylopyranosyl)-β-(D-glucopyranosyl)-CK, 20-O-Glucosylginsenoside Rf, and Ginsenoside F3. Glycosyltransferase in the present invention can further be applied to construction of artificially synthesized ginsenoside, novel ginsenoside, and derivatives thereof.

IPC Classes  ?

• C12N 9/10 - Transferases (2.)
• C12P 19/18 - Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
• C12P 19/56 - Preparation of O-glycosides, e.g. glucosides having an oxygen atom of the saccharide radical directly bound to a condensed ring system having three or more carbocyclic rings, e.g. daunomycin, adriamycin
• C12N 15/54 - Transferases (2)
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• A01H 5/00 - Angiosperms, i.e. flowering plants, characterised by their plant partsAngiosperms characterised otherwise than by their botanic taxonomy

Abstract

Provided are a gene SBI and SBI mutant protein for regulating crop dwarf and yield, and use thereof for regulating agronomic characters of crops. The agronomic characters are selected from one or more of (i) plant height, (ii) tiller number, (iii) grain weight per plant, and (iv) yield. The 308th amino acid (aspartic acid) of dwarf related proteins in the crop is mutated into asparagine, and/or the 338th amino acid (glycine) is mutated into arginine to significantly decrease the content of activated gibberellin GA1/GA9, and significantly increase the content of deactivated gibberellin GA8/GA51/GA29, so as to significantly decrease the plant height and improve the lodging-resistance capability of the crops.

IPC Classes  ?

• C07K 14/415 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from plants
• C12N 15/29 - Genes encoding plant proteins, e.g. thaumatin
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• A01H 5/00 - Angiosperms, i.e. flowering plants, characterised by their plant partsAngiosperms characterised otherwise than by their botanic taxonomy

Abstract

Provided in the present invention is the use of VCAM-1+ monocytes and derived cells thereof in promoting hematopoietic stem cells homing. In particular, provided in the present invention is a composition or a preparation promoting hematopoietic stem cells homing. Also provided in the present invention is a method for determining a potential therapeutic agent promoting hematopoietic stem cells homing.

IPC Classes  ?

• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12N 5/0786 - MonocytesMacrophages
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• A61K 35/14 - BloodArtificial blood
• A61P 35/02 - Antineoplastic agents specific for leukemia

Abstract

Provided are a cocktail-style CRISPR/Cas9 system (C-CRISPR) and a method for preparing a gene knockout animal, the gene function of which is completely knocked out or mostly knocked out, by using the system.

IPC Classes  ?

• C12N 15/90 - Stable introduction of foreign DNA into chromosome
• C12N 15/89 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection

Abstract

Disclosed is the use of ALDH1A and an agonist, a catalysate and an inhibitor thereof. In particular, disclosed is the use of ALDH1A or an agonist thereof or a catalysate thereof in the preparation of a pharmaceutical composition or a preparation, wherein the pharmaceutical composition or preparation is used to treat and/or prevent autism.

IPC Classes  ?

• A61K 31/203 - Retinoic acids
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

The present invention provides a cytochrome P450 mutant protein and applications thereof. In particular, in the present invention, after the modification of key sites in the cytochrome P450 CYP716A47, the PPD production and the PPD/DM proportion can be significantly improved.

IPC Classes  ?

• C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
• C12N 15/53 - Oxidoreductases (1)
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• C12P 33/00 - Preparation of steroids
• A01H 5/00 - Angiosperms, i.e. flowering plants, characterised by their plant partsAngiosperms characterised otherwise than by their botanic taxonomy

Abstract

Provided is a chloroplast genome editing method. In particular, provided are a nucleic acid construct, a vector, or a vector combination for plant genome site-specific editing based on a CRISPR technology, and a plant genome site-specific editing method. The nucleic acid construct comprises a nucleic acid construct of formula I and/or a nucleic acid construct of formula II, the nucleic acid construct of formula I comprises a chloroplast targeting signal peptide-nuclease expression cassette, and the nucleic acid construct of formula II comprises an ncRNA-sgRNA expression cassette. With this method, a nuclease and a corresponding sgRNA can be introduced into a chloroplast, so that gene knockout or homologous recombination and targeted insertion of a foreign segment can be carried out simply and efficiently at a predetermined chloroplast genomic site. This method can be used to improve a trait of a crop from the chloroplast genome level.

IPC Classes  ?

• C12N 15/09 - Recombinant DNA-technology
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 15/66 - General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligationUse of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease

Abstract

Disclosed is a site-directed editing method for plant genome based on Cpf1. In particular, disclosed are a nucleic acid construct, vector or vector combination for plant genome site-directed editing based on Cpf1 (AsCpf1, FnCpf1, LbCpf1), and a site-directed editing method for plant genome. In particular, the nucleic acid construct comprises a first expression cassette and an optional second expression cassette. The first expression cassette is a Cpf1-NLS fusion protein expression cassette. The second expression cassette is a crRNA expression cassette. With the method, the single-gene knockout, multiple-gene knockout or homologous recombination and directional insertion of foreign fragments can be performed simply and efficiently at a predetermined plant genomic site.

IPC Classes  ?

• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells

Abstract

Disclosed are a nucleic acid construct having a particular structure, and a method for a base mutation or a base substitution on a particular site of a plant genome using the construct. The nucleic acid construct comprises a first expression cassette, a second expression cassette and an optional third expression cassette, wherein the first expression cassette is an expression cassette for expressing gRNAs, the second expression cassette is an expression cassette for expressing a fusion protein comprising a CAS9 and cytosine deaminase, and the third expression cassette is an expression cassette for expressing a selection marker.

IPC Classes  ?

• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• C12N 9/78 - Hydrolases (3.) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
• A01H 5/00 - Angiosperms, i.e. flowering plants, characterised by their plant partsAngiosperms characterised otherwise than by their botanic taxonomy

Abstract

Provided is the use of an insulin-like growth factor-2 for preparing a pharmaceutical composition, wherein the pharmaceutical composition is used for (i) promoting the expression of the macrophage PD-L1, and/or (ii) inhibiting the expression of the macrophage IL-1β. Also provided is a pharmaceutical composition containing the insulin-like growth factor-2 as an active ingredient.

IPC Classes  ?

• A61K 38/30 - Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
• A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 37/04 - Immunostimulants
• A61P 37/02 - Immunomodulators
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 5/50 - Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• C12N 5/0786 - MonocytesMacrophages

Abstract

Provided is a plant genome site-specific knock-in method. The method modifies a donor DNA fragment, wherein a target gene is cleaved at a specific site with a site-specific cleavage nuclease, and the donor DNA fragment is integrated into the cleavage site. The method can efficiently and site-specifically integrate a donor DNA fragment into the genome of an acceptor plant.

IPC Classes  ?

• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells

Abstract

Provided are a nucleic acid construct replicating or expressing an exogenous gene in plant cells and the use thereof. Also provided are a vector, plant cells and plants comprising the construct.

IPC Classes  ?

• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• A01H 5/00 - Angiosperms, i.e. flowering plants, characterised by their plant partsAngiosperms characterised otherwise than by their botanic taxonomy

Abstract

A novel modification of 5-methylcytosine catalyzed by a Cmd1 enzyme and an application thereof. The Cmd1, a 5mC-modifying enzyme, can link a glycerol group to the 5mC methyl carbon of a methylated nucleic acid through a carbon-carbon single bond.

IPC Classes  ?

• C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12N 9/02 - Oxidoreductases (1.), e.g. luciferase

Abstract

A cotton GhTCP4 gene and an application thereof in modifying the length of a cotton fiber. The cotton GhTCP4 gene is isolated, cloned and subjected to functional identification, and an expression level of the GhTCP4 gene is regulated by molecular biology and transgenic technology, so as to make adjustment to plant growth and development, thereby obtaining a transgenic cotton having significantly longer fibers. The function and use of a GhTCP4 transcriptional factor-like protein in cotton have a positive effect on promoting the elongation of fibroblasts and improving the length and quality of cotton fibers, and thus have a broad application prospect.

IPC Classes  ?

• C12N 15/29 - Genes encoding plant proteins, e.g. thaumatin
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C07K 14/415 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from plants

Abstract

Provided are a fusion protein producing a point mutation in a cell, and preparation and use thereof. The fusion protein includes or is formed by a cytosine deaminase and Cas enzyme in which the nuclease activity is deficient but the helicase activity retains. Also provided are the coding sequence of the fusion protein, a polynucleotide sequence containing the coding sequence, a nucleic acid construct containing the polynucleotide sequence, the corresponding host cell, a method for producing the point mutation in the cell, and a kit, etc. The method can achieve site-directed mutagenesis, and at the same time, achieve high mutation efficiency and multiple mutation combinations in a particular gene region.

IPC Classes  ?

• C12N 9/78 - Hydrolases (3.) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
• C07K 19/00 - Hybrid peptides
• C12N 15/09 - Recombinant DNA-technology

Abstract

Disclosed is a method for removing 5'and 3' linker connection by-products in a construction based on a sequencing library. In particular, provided is a method for cleaving an RNA-DNA : cDNA hybrid duplex, comprising the step of mixing a Cas enzyme, an sgRNA and the RNA-DNA : cDNA hybrid duplex, wherein the DNA moiety in the hybrid duplex comprises a protospacer-adjacent motif (PAM sequence) recognized by the Cas enzyme; the sgRNA can specifically bind to a portion of the cDNA strand; and the Cas enzyme can specifically recognize the sgRNA and cleave the hybrid duplex; optionally, the RNA-DNA : cDNA hybrid duplex is generated during the construction of the RNA sequencing library; and optionally, the RNA is the 5' linker used during the construction of the RNA sequencing library, and the DNA is the 3' linker used during the construction of the RNA sequencing library.

IPC Classes  ?

• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides
• C40B 50/06 - Biochemical methods, e.g. using enzymes or whole viable microorganisms
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

Provided are an SPL gene and an application thereof in improving heat tolerance of plants, and in particular, a function and use of the SPL gene. The SPL gene, SPL1 or SPL12, is a key factor necessary for high-temperature adaptation and tolerance of a plant and for maintaining maturation and germination of a seed under high temperature. Transgenic Arabidopsis thaliana overexpressing SPL1 or SPL2 can improve the tolerance of floral organs to extreme temperatures and high temperature.

IPC Classes  ?

• C12N 15/29 - Genes encoding plant proteins, e.g. thaumatin
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• C07K 14/415 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from plants
• A01H 5/00 - Angiosperms, i.e. flowering plants, characterised by their plant partsAngiosperms characterised otherwise than by their botanic taxonomy

Abstract

Disclosed is a small molecule compound composition that efficiently induces the differentiation of human pluripotent stem cells into myocardial cells. In particular, provided in the present invention is a small molecule compound composition. The small molecule compound composition comprises the following components: (i) an mTOR signaling pathway inhibitor; (ii) a Wnt pathway promoter; and (iii) optionally, a pharmaceutically acceptable carrier. The small molecule compound composition in the present invention can efficiently induce the differentiation of human pluripotent stem cells into myocardial cells. The preliminarily screened cardiomyocyte differentiation rate reaches up to 86%, and the optimized cardiomyocyte differentiation rate reaches up to 98.3%.

IPC Classes  ?

• A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• C12N 5/0735 - Embryonic stem cellsEmbryonic germ cells
• A61K 35/34 - MusclesSmooth muscle cellsHeartCardiac stem cellsMyoblastsMyocytesCardiomyocytes
• A61P 9/00 - Drugs for disorders of the cardiovascular system

Abstract

Provided are methods and compositions for the treatment of cancer using an ACAT1 inhibitor. The cancer may be any of melanoma, lymphoma, esophageal cancer, liver cancer, head and neck cancer, bladder cancer, endometrial cancer, kidney cancer and thyroid cancer. In some embodiments, the cancer itself it not responsive directly to the ACAT1 inhibitor but is rather treated through the immune system activated by the ACAT1 inhibitor. Combination therapies are also provided, for instance in combination with an alkylating antineoplastic agent.

IPC Classes  ?

• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/255 - Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
• A61K 31/4164 - 1,3-Diazoles
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention provides methods and compositions for activating a CD8+ T cell which is useful for cancer immunotherapy and treating infections. The CD8+ T cell can be activated by contacting with an agent that increases the plasma membrane cholesterol level of the cell. Also provided are methods and agents for screening for agents useful for inhibiting CD8+ T cells.

IPC Classes  ?

• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells

Abstract

The present disclosure provides methods and compositions for the treatment of cancer using an ACAT1 inhibitor in combination with an immune checkpoint inhibitor. The immune checkpoint inhibitor may inhibit the programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), lymphocyte-activation protein 3 (LAG-3), or combinations thereof. The ACAT1 inhibitor may be avasimibe, pactimibe, or purpactins, without limitation.

IPC Classes  ?

• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• A61P 35/02 - Antineoplastic agents specific for leukemia

Abstract

Disclosed are a high stress resistant plant growth regulator and a preparation method and use thereof. In particular, the compound provided by the present invention is an ABA substitute for significantly improving the stress resistance of plants, and therefore has a very wide application prospect.

IPC Classes  ?

• C07D 265/18 - 1,3-OxazinesHydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
• C07D 215/227 - Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
• C07D 239/80 - Oxygen atoms
• A01N 43/42 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings condensed with carbocyclic rings
• A01N 43/54 - 1,3-DiazinesHydrogenated 1,3-diazines
• A01N 43/86 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms, as ring hetero atoms six-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,3
• A01P 21/00 - Plant growth regulators

Abstract

Provided are parthenogenetic haploid embryonic stem cells, a preparation method therefor, and application of the parthenogenetic haploid embryonic stem cells in constructing gene modification semi-cloned animals and a gene modification semi-cloned animal library. H19-DMR and IG-DMR of the parthenogenetic haploid embryonic stem cells are knocked out. The parthenogenetic haploid embryonic stem cells are capable of stably obtaining survival SC mice by being injected in ova, and can be effectively used for polygenic inheritance operation, thereby further obtaining animals carrying polygenic inheritance modification.

IPC Classes  ?

• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/873 - Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
• C12N 15/867 - Retroviral vectors
• A01K 67/027 - New or modified breeds of vertebrates

Abstract

Disclosed are a small molecule compound for enhancing plant stress resistance, a preparation method therefor, and application thereof. Specifically, disclosed are compounds as shown in formula I, salts thereof, optical isomers thereof, racemes thereof, solvates thereof, or precursors thereof. Moreover, the compound of the present invention is a substitute of ABA, can significantly improve the plant stress resistance, and thus has an extremely wide application prospect.

IPC Classes  ?

• C07D 215/38 - Nitrogen atoms
• A01N 43/42 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings condensed with carbocyclic rings
• A01N 3/00 - Preservation of plants or parts thereof, e.g. inhibiting evaporation, improvement of the appearance of leavesGrafting wax
• A01P 21/00 - Plant growth regulators

Abstract

Provided is an adipose-derived stem cell in which a thromboxane A2 receptor (TP) is deactivated or inhibited and/or the activity of a calpain is deactivated or reduced, and/or the activity of a β-catenin is enhanced. Also provided are a use of an adipose-derived stem cell in preparing drugs for treating ischemic diseases and a method of preparing a vascular endothelial cell or blood vessel from an adipose-derived stem cell. Also provided is a method of enhancing pro-angiogenic capability of an adipose-derived stem cell or promoting differentiation of an adipose-derived stem cell into a vascular endothelial cell. Also provided are uses of a TP antagonist and/or a calpain inhibitor in preparing drugs for promoting differentiation capability of an adipose-derived stem cell into a vascular endothelial cell and improving angiogenesis thereof.

IPC Classes  ?

• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Provided are a ribozyme-enhanced short hairpin RNA (shRNA) and manufacturing method and application thereof. The 5' end to the 3' end of the ribozyme-enhanced shRNA, sequentially, are: (a) a 5' end pairing region; (b) a top loop region; (c) a 3' end pairing region, wherein the 5' end pairing region and the 3' end pairing region form a double-stranded region, and the length of the double-stranded region is greater than or equal to 19 bp; (d) a 3' end unpaired region; (e) a ribozyme region connected to the 3' end unpaired region. The ribozyme-enhanced shRNA can produce a small interfering RNA (siRNA), and a nucleotide sequence of the siRNA corresponds to the 3' end pairing region or the 5' end pairing region. The present invention significantly improves the siRNA production efficiency of the ribozyme-enhanced shRNA and has a higher inhibitory efficiency towards a target gene.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

An androgenetic haploid embryonic stem cell in which H19 DMR and IG-DMR thereof have been knocked out, method of preparing the androgenetic haploid embryonic stem cell, and use of the androgenetic haploid embryonic stem cell in constructing a genetically modified semi-cloned animal and a library of a genetically modified semi-cloned animal. The androgenetic haploid embryonic stem cell can obtain characteristics resembling a round spermatid, and on injection into an egg a viable SC mouse can be stably obtained. The invention can be effectively used in multi-gene genetic manipulation, advancing the acquisition of animals with multiple genetic modifications.

IPC Classes  ?

• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• C12N 5/0735 - Embryonic stem cellsEmbryonic germ cells

Abstract

Provided are a gene for negatively regulating the resistance of a plant against Delphacidae insects and a use thereof.

IPC Classes  ?

• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• C12N 15/29 - Genes encoding plant proteins, e.g. thaumatin

Abstract

Disclosed is a use of artepillin C and analogs thereof in the preparation of a drug for preventing and treating metabolic diseases. The present invention is the first to disclose a significant effect of artepillin C or analogs thereof in preventing and treating metabolic diseases, thus providing a multifunctional drug focusing on the regulation of CREB/CRTC2 or SREBP.

IPC Classes  ?

• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

Disclosed are a mesenchymal stem cell hypoxically cultured and the use thereof, wherein the stem cell can relieve or treat inflammatory diseases, thereby producing an insulin-like growth factor-2 which plays a central role in the treatment of inflammatory diseases by means of the mesenchymal stem cell hypoxically cultured.

IPC Classes  ?

• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61P 37/02 - Immunomodulators
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system

Abstract

Provided is a method for calculating a photosynthetic rate of a crown, which is used in fields such as basic research of crowns of plants and breeding of agricultural crops, and is used to measure influence of cultivation measures on a photosynthetic rate of a crown of a plant. The method comprises: constructing a three-dimensional structure of a crown for a plant type parameter and a planting parameter by using a crown reconstruction method; obtaining light intensity distribution on each leaf inside the crown by using a ray tracing algorithm and based on the constructed three-dimensional structure of the crown; obtaining a leaf metabolic feature parameter, and parameterize a plant leaf metabolic model; and calculating a photosynthetic rate of the entire crown by combining the constructed three-dimensional structure of the crown, the obtained light intensity distribution on each leaf, and the parameterized plant leaf metabolic model.

IPC Classes  ?

• G06F 19/00 - Digital computing or data processing equipment or methods, specially adapted for specific applications (specially adapted for specific functions G06F 17/00;data processing systems or methods specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes G06Q;healthcare informatics G16H)

Abstract

Disclosed are a protein molecular maker Dkk-3 protein related to muscle atrophy, and an application thereof in the diagnosis of diseases of muscle atrophy. Compared with that in normal muscle cells, the expression of the Dkk-3 protein is obviously high in muscle atrophy cells, and therefore the Dkk-3 protein can be used as an effective marker for detecting muscle atrophy.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

Provided in the present invention are a pharmaceutical compositions and kits containing rapamycin or an analogue thereof, and chemotherapy drugs for treating tumours or reversion of tumour resistance, and a use of rapamycin and an analogue thereof in manipulating the tumour microenvironment to reverse tumor resistance by targeting mTOR.

IPC Classes  ?

• A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61K 31/136 - Amines, e.g. amantadine having aromatic rings, e.g. methadone having the amino group directly attached to the aromatic ring, e.g. benzeneamine
• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• A61P 35/00 - Antineoplastic agents

Abstract

Disclosed is athe use of an antibody specifically targeting WNT16B in the preparation of an anti-tumor medicine. The antibody specifically targeting WNT16B can inhibit the biological activity of WNT16B effectively, promote the apoptosis response of tumor cells, prevent the tumor acquiring resistance from the microenvironment activated by injury, increase the tumor sensitivity to chemotherapeutics, and improve the therapeutic effect of anti-tumor treatment ultimately.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 35/00 - Antineoplastic agents
• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61K 31/136 - Amines, e.g. amantadine having aromatic rings, e.g. methadone having the amino group directly attached to the aromatic ring, e.g. benzeneamine
• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine

Abstract

Provided are a mutant protein of glycosyltransferase and uses thereof. Specifically, by using homology alignment and site-directed mutagenesis, a new mutant protein of glycosyltransferase is discovered. The mutant protein is a non-natural protein with glycosyltransferase catalytic activity, which contains the following core amino acids related to enzyme catalytic activity: the amino acid at position 142 is A, the amino acid at position 144 is H or F and the amino acid at position 339is G, wherein the number of the amino acid position is based on the sequence shown in SEQ ID NO: 13.

IPC Classes  ?

• C12N 9/10 - Transferases (2.)
• C12N 15/54 - Transferases (2)
• C12N 15/70 - Vectors or expression systems specially adapted for E. coli
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• A01H 5/00 - Angiosperms, i.e. flowering plants, characterised by their plant partsAngiosperms characterised otherwise than by their botanic taxonomy
• C12P 33/20 - Preparation of steroids containing heterocyclic rings

Abstract

Provided are mesenchymal stem cells (MSCs) pre-treated by I-type interferon (IFN) or over-expressing the I-type IFN, and use of the MSCs in the preparation of antineoplastic drug. Also provided is a use of the I-type IFN in the preparation of a composition for improving the expression of MHC I in the MSCs, reducing the immunosuppression ability of the MSCs, improving the antitumor immune response of organism, inhibiting the DNA combining ability of STAT1 in the MSCs and reducing the expression of inducible nitric oxide synthase (iNOS) in the MSCs.

IPC Classes  ?

• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 38/21 - Interferons
• A61P 35/00 - Antineoplastic agents

Abstract

A reagent for improving the survival rate of CD4 positive T-lymphocytes and an application thereof. A histone deacetylase inhibitor can depress an activation-induced cell death (AICD) process of T-lymphocytes. The histone deacetylase inhibitor comprises trichostatin A and sodium butyrate. A combination of the histone deacetylase inhibitor and an anti-CTLA-4 antibody has a synergistic anti-tumor effect.

IPC Classes  ?

• A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61P 35/00 - Antineoplastic agents

Abstract

Uses of an achaete-scute complex homolog-like 1 (Ascl1) gene or a protein thereof or an accelerator thereof: (i) use in preparing a pharmaceutical composition for inducing astrocytes to become functional neuron cells; and/or (ii) use in preparing a pharmaceutical composition for treating neurological disorders such as neurodegenerative pathologies, central nervous system trauma, and so on.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 25/00 - Drugs for disorders of the nervous system
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms

Abstract

The present invention provides a new plant gene-rice high temperature resistance 1 gene (Rice High Temperature Resistance 1, HTR1) and encoded protein thereof. Also disclosed is the use of the high temperature resistance gene, especially for the enhancement of high-temperature resistance of plants in plant variety improvement and cross breeding.

IPC Classes  ?

• C07K 14/415 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from plants
• C12N 15/29 - Genes encoding plant proteins, e.g. thaumatin
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• A01H 1/00 - Processes for modifying genotypes
• A01H 5/00 - Angiosperms, i.e. flowering plants, characterised by their plant partsAngiosperms characterised otherwise than by their botanic taxonomy

Abstract

The present invention provides a new method for reducing the synthesis of cholesterol and fat on the basis of PAQR3. Specifically, disclosed is that PAQR3 is involved in the biosynthesis of cholesterol and lipid. PAQR3 is a membrane protein distributed on the Golgi apparatus, and it anchors SREPB and Scap to the Golgi apparatus by binding to them and promotes SREBP to synthesize cholesterol and lipid. By the regulation of PAQR3 activity, the synthesis of cholesterol and fat could be regulated.

IPC Classes  ?

• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
• G01N 33/15 - Medicinal preparations
• A61P 3/06 - Antihyperlipidemics

Abstract

Provided is a stress-sensitive miR-103a exhibiting a regulatory effect in bone formation, playing an important role in osteoblast differentiation and serving as a target in the prevention and treatment of bone metabolism diseases (including osteoporosis, abnormal osteogenic differentiation and bone loss). The down-regulation agent of miR-103a improves the osteoporosis phenotype caused by stress loss.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• A61P 19/08 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
• A61P 19/10 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Abstract

Provided in the present application is a synthetic gene cluster of cordycepin, comprising Cm1, Cm2, and/or Cm3, corresponding to homologous genes An1, An2 and/or An3 in Aspergillus nidulans. Also provided in the present application is a method for realizing the biosynthesis of cordycepin.

IPC Classes  ?

• C12P 19/40 - Nucleosides having a condensed ring system containing a six-membered ring having two nitrogen atoms in the same ring, e.g. purine nucleosides
• C12N 15/31 - Genes encoding microbial proteins, e.g. enterotoxins
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression

Abstract

Provided herein are methods for diagnosing and/or treating triple negative breast cancers (TNBC), as well as compositions and kits that can be used in such methods. In one aspect, protein C receptor (PROCR) can be used in the diagnosis and/or treatment of TNBC, wherein the PROCR is selected from Procr gene, Procr mRNA and/or PROCR protein. The TNBC treatment can include one or more of: (i) RCR-252 antibody, or antigen binding fragment thereof; (ii) an isolated anti-PROCR antibody or antigen binding fragment thereof wherein the antibody cross-competes for binding to PROCR with RCR-252; (iii) soluble PROCR fragment; (iv) the interfering RNA designed to target Procr mRNA, and (v) CRISPR/Cas9 designed to target Procr gene.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents

Abstract

Provided are a method for improving the heterologous synthesis of Escherichia coli into polyketides and use of same. Particularly, the present invention weakens the expression of 72 genes in host bacteria such as sucC and talB, thus dramatically improving the yield of heterologous synthesis of Escherichia coli into polyketides.

IPC Classes  ?

• C12N 15/70 - Vectors or expression systems specially adapted for E. coli
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12P 17/08 - Oxygen as only ring hetero atoms containing a hetero ring of at least seven ring members, e.g. zearalenone, macrolide aglycons

Abstract

A group of glycosyltransferases and a use thereof are disclosed in the present invention. Specifically, the use of glycosyltransferase gGT29-7 and a polypeptide derived therefrom in catalytic glycosylation of a terpenoid and in synthesizing new saponins is provided. The glycosyltransferase is able to specifically and highly efficiently transfer a glycosyl from a glycosyl donor to a first glycosyl at the C-3 position and/or the C-6 position of a 4-ring triterpenoid, so as to extend the carbohydrate chain. The gylcosyltransferases of the present invention may also be used in constructing artificially synthesized ginsenosides and a variety of new ginsenosides and derivatives thereof.

IPC Classes  ?

• C12P 19/18 - Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
• C12P 33/00 - Preparation of steroids
• C07K 14/415 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from plants
• C12N 9/10 - Transferases (2.)
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 15/54 - Transferases (2)
• A01H 4/00 - Plant reproduction by tissue culture techniques

Abstract

Provided is a method for promoting soluble expression of recombinant extremely thermostable α-amylase, containing a co-expression of a gene encoding extremely thermostable α-amylase and a gene encoding the molecular chaperone protein Prefoldin; thus the soluble expression and enzyme activity of extremely thermostable α-amylase are improved.

IPC Classes  ?

• C12N 9/28 - Alpha-amylase from microbial source, e.g. bacterial amylase
• C07K 14/195 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria
• C12R 1/19 - Escherichia coli

Abstract

Provided are uses of IL-17 in enhancing an immune-suppression function of mesenchymal stem cells. In particular, the present invention provides uses of an interleukin-17, a derivative of interleukin-17 or an agonist thereof for preparing a preparation or kit for enhancing an immune-suppression function of the mesenchymal stem cells; up-regulating the expression of imunosuppressive factors in the mesenchymal stem cells; enhancing the stability of mRNAs of the immunosuppressive factors; reducing the expression level of RNA-binding protein AUF1; inhibiting the proliferation of T cells; and treating hepatitis or liver damage.

IPC Classes  ?

• A61K 38/20 - Interleukins
• A61K 38/21 - Interferons
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells
• C07K 19/00 - Hybrid peptides
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

Provided is a new 13α-kaurenoic acid hydroxylase, the encoding gene and the uses thereof. The new 13α-kaurenoic acid hydroxylase is obtained by cloning from Stevia Rebaudiana Bertoni for the first time, and used for the heterogeneous bio-synthesis of stevioside successfully.

IPC Classes  ?

• C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
• C12N 15/53 - Oxidoreductases (1)
• C12N 15/29 - Genes encoding plant proteins, e.g. thaumatin
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C13K 13/00 - Sugars not otherwise provided for in this class

Abstract

Provided is a nicotinamide adenine dinucleotide (NADPH)-cytochrome P450 reductase and a use thereof. Also provided is a polynucleotide encoding the NADPH-cytochrome P450 reductase, an expression vector and a host cell which express the NADPH-cytochrome P450 reductase, and a method for producing the protopanoxadiol.

IPC Classes  ?

• C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
• C12N 15/53 - Oxidoreductases (1)
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 15/70 - Vectors or expression systems specially adapted for E. coli
• C12N 15/75 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
• C12N 15/81 - Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
• C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
• C12P 33/00 - Preparation of steroids

Abstract

Provided are methods of producing a neuronal phenotype in a glial cell or somatic non-neuronal cell. The methods comprise contacting the glial cell or the somatic non-neuronal cell with a composition including small molecules. Also provided are methods for screening for a therapeutic agent for a neurological condition of a subject.

IPC Classes  ?

• C12N 5/07 - Animal cells or tissues
• C12N 5/0797 - Stem cellsProgenitor cells
• A61K 35/30 - NervesBrainEyesCorneal cellsCerebrospinal fluidNeuronal stem cellsNeuronal precursor cellsGlial cellsOligodendrocytesSchwann cellsAstrogliaAstrocytesChoroid plexusSpinal cord tissue
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

Provided are a method for inducing the transdifferentiation of somatic cells into neural stem cells and application for same. Using a combination of a histone deacetylase (HDAC) inhibitor, a glycogen synthase kinase (GSK-3) inhibitor, and a transforming growth factor β (TGF-β) signal pathway inhibitor, in a low-oxygen normal physiological environment, induce somatic cells such as fibroblasts and epithelial cells to form into neural stem cells having good pluripotency and passage stability.

IPC Classes  ?

• C12N 5/07 - Animal cells or tissues
• C12N 5/0797 - Stem cellsProgenitor cells
• A61K 35/30 - NervesBrainEyesCorneal cellsCerebrospinal fluidNeuronal stem cellsNeuronal precursor cellsGlial cellsOligodendrocytesSchwann cellsAstrogliaAstrocytesChoroid plexusSpinal cord tissue
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

A detection device (1) and detection method for detecting a pre-disease state. The device (1) comprises a sample acquisition unit (10), wherein the sample acquisition unit (10) acquires comparison sample data and single sample data of a detection object; a DNB setting unit (11), wherein the DNB setting unit (11) sets DNB members; index calculation units (13, 14, 15, 16), wherein the index calculation units (13, 14, 15, 16) obtain composite indexes by calculating the distance between the probability distribution of the comparison sample data and the single sample data; and a state judgement unit (12), wherein the state judgement unit (12) judges that the detection object is in a pre-disease state when the composite indexes exceed a threshold value. Therefore, the DNB theory is effectively applied to single sample conditions, so that the pre-disease state can be simply and accurately detected.

IPC Classes  ?

• G06F 19/24 - for machine learning, data mining or biostatistics, e.g. pattern finding, knowledge discovery, rule extraction, correlation, clustering or classification
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

Provided is a compound represented by formula I, wherein R9 is a C1-C22 hydrocarbyl group or a C2-C3 ester-substituted C1-C3 alkyl group, R5, R6, R7 and R8 are alkyl groups or H, and R1, R2, R3 and R4 are H or lower hydrocarbyl groups. Or, R9 is a C2-C22 hydrocarbyl group or a C2-C3 ester-substituted C1-C3 alkyl group, and R5 is connected to R1, R6 is connected to R2, R7 is connected to R3 and R8 is connected to R4 to form six-membered rings. The present compound is temperature-sensitive and can enter into cells. An intracellular temperature distribution image having high spatial and temporal resolution can thus be obtained. The present compound can also perform distribution calibration on a temperature-sensitive fluorescent compound. Also provided is a method for measuring temperature distribution within a living cell, and a corresponding detection kit. The method satisfies the requirements of small size measurement and rapid measurement, thereby achieving high resolution in terms of space and time.

IPC Classes  ?

• C07D 311/82 - Xanthenes
• C07D 491/22 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or in which the condensed system contains four or more hetero rings
• C07D 471/04 - Ortho-condensed systems
• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials
• G01K 11/00 - Measuring temperature based on physical or chemical changes not covered by group , , , or

Abstract

The present invention relates to the application of a specific inhibitor for an SHH signaling pathway. Disclosed for the first time are that the SHH signaling pathway and excitability of neural networks have a close relationship and are involved in the formation and development of epilepsy, and are thus able to act as drug targets for developing drugs for improving or treating epilepsy. Also disclosed is a specific inhibitor for SHH signaling pathway capable of delaying epileptogenesis and being used as a drug for improving or treating epilepsy.

IPC Classes  ?

• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
• A61P 25/08 - AntiepilepticsAnticonvulsants

Abstract

Provided are extracellular matrix protein 1(ECM1) and fusion protein Fc-EcMI of the ECM1 and the Fc sequence, and also provided are cloning, construction and expression of the protein, and use of the protein in preparing a pharmaceutical composition used for treating multiple sclerosis.

IPC Classes  ?

• C07K 19/00 - Hybrid peptides
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 15/866 - Baculoviral vectors
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 37/02 - Immunomodulators

Abstract

Provided is a gene regulating rice plant-type and use thereof. Specifically, provided is an OsREM4.1 protein the coding gene thereof capable of regulating the plant type of rice. The protein and the coding gene thereof can not only regulate the height, the leaf inclination and the leaf rolling index of plants, such as rice, but also be used to enhance the yield of rice and improve the lodging resistance, drought resistance, salt resistance, and cold resistance and the like of the plant. Also provided is a method for improving plants, such as rice, by using the OsREM4.1 protein and the coding gene thereof.

IPC Classes  ?

• A01H 1/00 - Processes for modifying genotypes
• C12N 15/09 - Recombinant DNA-technology

Abstract

An RNAi method for control of growth-related genes of plant-eating pests and applications thereof, a dsRNA preparation and method for the use thereof.

IPC Classes  ?

• C12N 15/87 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
• C12N 15/12 - Genes encoding animal proteins
• A01N 57/16 - Biocides, pest repellants or attractants, or plant growth regulators containing organic phosphorus compounds having phosphorus-to-oxygen bonds or phosphorus-to-sulfur bonds containing heterocyclic radicals
• A01P 7/04 - Insecticides

Abstract

Provided are an endo-xylanase and a coding gene and the use thereof. Also provided are an expression vector and a host cell containing the coding gene, a method for forming a simple sugar by using the xylanase, a xylanase mutant with an improved thermal stability and a method for improving the thermal stability of the xylanase.

IPC Classes  ?

• C12N 9/42 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on beta-1, 4-glucosidic bonds, e.g. cellulase
• C12N 15/56 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. amylase, galactosidase, lysozyme
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
• C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12P 19/14 - Preparation of compounds containing saccharide radicals produced by the action of a carbohydrase, e.g. by alpha-amylase
• C12P 19/00 - Preparation of compounds containing saccharide radicals
• C12P 19/02 - Monosaccharides
• C12P 19/12 - Disaccharides
• C12Q 1/34 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase
• A23L 1/29 - Modifying nutritive qualities of foods; Dietetic products ( A23L 1/09 takes precedence;dietetic salt substitutes A23L 1/22)

Abstract

Provided in the present invention are a depression regulatory factor and applications thereof. Specifically, provided in the present invention are applications of βCaMKII inhibitor in preparation of a medicament for prevention and/or treatment of depression. A study of the present invention shows that core depression symptoms such as anhedonia and behavioral despair can be induced by overexpression of βCaMKII (and not αCaMKII) at the lateral habenula; and, lowering at the lateral habenula of the expression level of βCaMKII either to reduce the kinase activity of same or to block downstream molecule GluR1 of same allows for reversal of a depression phenotype of an animal.

IPC Classes  ?

• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 38/02 - Peptides of undefined number of amino acidsDerivatives thereof
• A61K 49/00 - Preparations for testing in vivo
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• G01N 33/573 - ImmunoassayBiospecific binding assayMaterials therefor for enzymes or isoenzymes
• A61P 25/24 - Antidepressants

Abstract

Provided is a method for plant genome site-directed modification. Specifically, a method for plant genome site-directed modification introduced by RNA is provided. By utilizing nucleic acid construct with particular structure, site-directed modification may be performed at pre-determined site in plant genome with high efficiency. Useful for screening plant with improved traits efficiently.

IPC Classes  ?

• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides

Abstract

Disclosed are a polypeptide regulating and controlling the formation of plant agronomic traits and yield traits, and use of the polypeptide. The present invention changes agronomic traits and yield traits such as plant root development, tillering capacity, heading time, ear type and structure, seed number and seed morphology of each ear and thousand-seed weight by directionally regulating and controlling the expression level of cytokinin-O-dextrose glycosyltransferase 1 in plants, thus improving plant types, the ear types and structure, and seed morphology and weight, and increasing yield.

IPC Classes  ?

• C12N 15/54 - Transferases (2)
• C12N 9/10 - Transferases (2.)
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

Provided is a muscle stem cell in vitro culture method. A muscle stem cell is cultivated in vitro by using a cell culture medium of a cell factor added with a blood cell or a conditioned medium of the blood cell. Also provided are a culture medium used in the muscle stem cell in vitro culture method and an application thereof.

IPC Classes  ?

• C12N 5/074 - Adult stem cells
• A61K 35/34 - MusclesSmooth muscle cellsHeartCardiac stem cellsMyoblastsMyocytesCardiomyocytes
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system

Abstract

Disclosed in the invention are a pancreatic neuroendocrine tumour susceptibility gene loci and detection methods and kits. In particular, disclosed in the invention is a pancreatic neuroendocrine tumour susceptibility gene loci based on whole genome sequencing findings, the loci is a high frequency T372R somatic mutation of a YY1 (Yin Yang1) gene. Also disclosed in the invention are methods for the detection of pancreatic neuroendocrine tumour susceptibility and pancreatic neuroendocrine tumour subtype classification, and corresponding detection kits.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof